Phio Pharmaceuticals Announces “A Groundbreaking Approach to Treating Skin Cancer” in a Fireside Chat with Force Family Office

Mar 16, 2026 | Press Releases

Registration link below for Wednesday March 18, 2026 at 4 PM EDT Phio invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend this virtual event King of Prussia,...

Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT

Mar 10, 2026 | Press Releases

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.comKing of Prussia, Pennsylvania–(Newsfile Corp....

Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update

Mar 5, 2026 | Press Releases

Treatment Phase for Lead Clinical Candidate PH-762 Dose Escalation Trial is Complete with Favorable Safety, Tolerability and Pathology Data 2025 Financings and Warrant Exercises Strengthen Balance Sheet with $23.7 Million in Net Proceeds, Extending Cash Runway into...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Mar 5, 2026 | Press Releases

Live Presentation and Q&A: Monday, March 9, 2026 10 AM EDTCEO to Discuss INTASYL Platform and PH-762 Phase 1b Results King of Prussia, Pennsylvania–(Newsfile Corp. – March 5, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage...

Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894

Feb 19, 2026 | Press Releases

Leadership Enhancements Position Company for Upcoming Regulatory Engagement and Clinical MilestonesNew Appointments Reinforce Operational Readiness Across Finance, Regulatory Affairs and Program LeadershipKing of Prussia, Pennsylvania–(Newsfile Corp. –...

Phio Announces Safety Monitoring Committee’s (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial

Feb 10, 2026 | Press Releases

Maximum Dose Concentration in Final Cohort Yields 85% Pathological Response (6 of 7 Patients); Complete Response (100% Tumor Clearance) in 4 of 6 RespondersNo Serious Adverse Events or Dose-Limiting Toxicities Identified Across All 5 Dose Escalation CohortsKing of...